162 related articles for article (PubMed ID: 22556352)
41. De novo large B-cell lymphoma in a parenchymal brain lesion: evidence of clonal evolution from splenic marginal zone lymphoma.
Fadugba O; Nguyen TT; McGill J; Wagner-Johnston N
J Clin Oncol; 2011 Mar; 29(9):e234-6. PubMed ID: 21205746
[No Abstract] [Full Text] [Related]
42. Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
Blood; 2023 Mar; 141(13):1647. PubMed ID: 36995700
[No Abstract] [Full Text] [Related]
43. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection.
Peveling-Oberhag J; Crisman G; Schmidt A; Döring C; Lucioni M; Arcaini L; Rattotti S; Hartmann S; Piiper A; Hofmann WP; Paulli M; Küppers R; Zeuzem S; Hansmann ML
Leukemia; 2012 Jul; 26(7):1654-62. PubMed ID: 22307176
[TBL] [Abstract][Full Text] [Related]
44. Primary nodal marginal zone lymphomas of splenic and MALT type.
Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
[TBL] [Abstract][Full Text] [Related]
45. Immunology. The paracaspase connection.
Yu L; Lenardo MJ
Science; 2003 Nov; 302(5650):1515-6. PubMed ID: 14645834
[No Abstract] [Full Text] [Related]
46. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract][Full Text] [Related]
47. Effective management strategies for patients with marginal zone lymphoma.
Rosand CB; Valla K; Flowers CR; Koff JL
Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
[TBL] [Abstract][Full Text] [Related]
48. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
Rossi D; Trifonov V; Fangazio M; Bruscaggin A; Rasi S; Spina V; Monti S; Vaisitti T; Arruga F; Famà R; Ciardullo C; Greco M; Cresta S; Piranda D; Holmes A; Fabbri G; Messina M; Rinaldi A; Wang J; Agostinelli C; Piccaluga PP; Lucioni M; Tabbò F; Serra R; Franceschetti S; Deambrogi C; Daniele G; Gattei V; Marasca R; Facchetti F; Arcaini L; Inghirami G; Bertoni F; Pileri SA; Deaglio S; Foà R; Dalla-Favera R; Pasqualucci L; Rabadan R; Gaidano G
J Exp Med; 2012 Aug; 209(9):1537-51. PubMed ID: 22891273
[TBL] [Abstract][Full Text] [Related]
49. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
50. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
51. An insidious presentation of splenic marginal zone lymphoma.
Burcheri S; Arcaini L; Della Porta M; Paulli M; Boveri E; Zibellini S; Rumi E; Algarotti A; Passamouti F; Lazzarino M
Clin Lymphoma Myeloma; 2007 May; 7(6):432-3. PubMed ID: 17621411
[TBL] [Abstract][Full Text] [Related]
52. Differential requirement for Malt1 in T and B cell antigen receptor signaling.
Ruland J; Duncan GS; Wakeham A; Mak TW
Immunity; 2003 Nov; 19(5):749-58. PubMed ID: 14614861
[TBL] [Abstract][Full Text] [Related]
53. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
54. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.
Arribas AJ; Rinaldi A; Mensah AA; Kwee I; Cascione L; Robles EF; Martinez-Climent JA; Oscier D; Arcaini L; Baldini L; Marasca R; Thieblemont C; Briere J; Forconi F; Zamò A; Bonifacio M; Mollejo M; Facchetti F; Dirnhofer S; Ponzoni M; Bhagat G; Piris MA; Gaidano G; Zucca E; Rossi D; Bertoni F
Blood; 2015 Mar; 125(12):1922-31. PubMed ID: 25612624
[TBL] [Abstract][Full Text] [Related]
55. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification.
Traverse-Glehen A; Baseggio L; Salles G; Felman P; Berger F
Curr Opin Oncol; 2011 Sep; 23(5):441-8. PubMed ID: 21760505
[TBL] [Abstract][Full Text] [Related]
56. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.
Bikos V; Darzentas N; Hadzidimitriou A; Davis Z; Hockley S; Traverse-Glehen A; Algara P; Santoro A; Gonzalez D; Mollejo M; Dagklis A; Gangemi F; Bosler DS; Bourikas G; Anagnostopoulos A; Tsaftaris A; Iannitto E; Ponzoni M; Felman P; Berger F; Belessi C; Ghia P; Papadaki T; Dogan A; Degano M; Matutes E; Piris MA; Oscier D; Stamatopoulos K
Leukemia; 2012 Jul; 26(7):1638-46. PubMed ID: 22222599
[TBL] [Abstract][Full Text] [Related]
57. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
58. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma.
Rinaldi A; Forconi F; Arcaini L; Mian M; Sozzi E; Zibellini S; Baldini L; Franceschetti S; Gaidano G; Marasca R; Mollejo M; Piris MA; Tucci A; Facchetti F; Bhagat G; Favera RD; Rancoita PM; Zucca E; Kwee I; Bertoni F
Br J Haematol; 2010 Dec; 151(5):435-9. PubMed ID: 21113978
[TBL] [Abstract][Full Text] [Related]
59. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
[TBL] [Abstract][Full Text] [Related]
60. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
